Where Will Hershey Stock Be In 1 Year?
Chocolate stocks used to be the epitome of sleepy stability,…
Sell
33
IRON Quote, Financials, Valuation and Earnings
Last price:
$54.82
Seasonality move
:
-13.32%
Day range:
$51.03 - $53.66
52-week range:
$30.82 - $68.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.79x
Volume:
503.7K
Avg. volume:
391.8K
1-year change:
27.75%
Market cap:
$1.8B
Revenue:
--
EPS (TTM):
-$3.92
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IRON
Disc Medicine
|
-- | -$1.14 | -- | -6.24% | $98.27 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.35 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IRON
Disc Medicine
|
$53.17 | $98.27 | $1.8B | -- | $0.00 | 0% | -- |
|
ATNM
Actinium Pharmaceuticals
|
$1.43 | $5.00 | $44.6M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.63 | $0.85 | $3.6M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.39 | -- | $22.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.44 | $1.00 | $1M | -- | $0.00 | 0% | 0.46x |
|
TOVX
Theriva Biologics
|
$0.45 | $7.00 | $3.7M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IRON
Disc Medicine
|
-- | 2.219 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.037 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IRON
Disc Medicine
|
-- | -$39.9M | -- | -- | -- | -$42.2M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Disc Medicine vs. Competitors
-
Which has Higher Returns IRON or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to Disc Medicine's net margin of -11511.11%. Disc Medicine's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$1.02 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About IRON or ATNM?
Disc Medicine has a consensus price target of $98.27, signalling upside risk potential of 84.83%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 249.65%. Given that Actinium Pharmaceuticals has higher upside potential than Disc Medicine, analysts believe Actinium Pharmaceuticals is more attractive than Disc Medicine.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is IRON or ATNM More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.
-
Which is a Better Dividend Stock IRON or ATNM?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or ATNM?
Disc Medicine quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Disc Medicine's net income of -$34.1M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Disc Medicine's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$34.1M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns IRON or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Disc Medicine's net margin of -49.65%. Disc Medicine's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$1.02 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About IRON or NBY?
Disc Medicine has a consensus price target of $98.27, signalling upside risk potential of 84.83%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that Disc Medicine has higher upside potential than NovaBay Pharmaceuticals, analysts believe Disc Medicine is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is IRON or NBY More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock IRON or NBY?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or NBY?
Disc Medicine quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Disc Medicine's net income of -$34.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Disc Medicine's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$34.1M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns IRON or NNVC?
Nanoviricides has a net margin of -- compared to Disc Medicine's net margin of --. Disc Medicine's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$1.02 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About IRON or NNVC?
Disc Medicine has a consensus price target of $98.27, signalling upside risk potential of 84.83%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 367.63%. Given that Nanoviricides has higher upside potential than Disc Medicine, analysts believe Nanoviricides is more attractive than Disc Medicine.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 NNVCNanoviricides0 0 0 -
Is IRON or NNVC More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock IRON or NNVC?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or NNVC?
Disc Medicine quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Disc Medicine's net income of -$34.1M is lower than Nanoviricides's net income of -$2.2M. Notably, Disc Medicine's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$34.1M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns IRON or OGEN?
Oragenics has a net margin of -- compared to Disc Medicine's net margin of --. Disc Medicine's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$1.02 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About IRON or OGEN?
Disc Medicine has a consensus price target of $98.27, signalling upside risk potential of 84.83%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1983.54%. Given that Oragenics has higher upside potential than Disc Medicine, analysts believe Oragenics is more attractive than Disc Medicine.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 OGENOragenics0 1 0 -
Is IRON or OGEN More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock IRON or OGEN?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or OGEN?
Disc Medicine quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Disc Medicine's net income of -$34.1M is lower than Oragenics's net income of -$2.2M. Notably, Disc Medicine's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$34.1M OGENOragenics0.46x -- -- -$2.2M
-
Which has Higher Returns IRON or TOVX?
Theriva Biologics has a net margin of -- compared to Disc Medicine's net margin of --. Disc Medicine's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine-- -$1.02 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About IRON or TOVX?
Disc Medicine has a consensus price target of $98.27, signalling upside risk potential of 84.83%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1455.56%. Given that Theriva Biologics has higher upside potential than Disc Medicine, analysts believe Theriva Biologics is more attractive than Disc Medicine.
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine8 0 0 TOVXTheriva Biologics1 1 0 -
Is IRON or TOVX More Risky?
Disc Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock IRON or TOVX?
Disc Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or TOVX?
Disc Medicine quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Disc Medicine's net income of -$34.1M is lower than Theriva Biologics's net income of -$4.3M. Notably, Disc Medicine's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine-- -- -- -$34.1M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will KNOT Stock Be In 1 Year?
In the case of KNOT Offshore Partners (KNOP), most headlines…
Why Is Goldman Sachs Stock Up So Much?
Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…
Stock Ideas
Buy
63
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 53x
Buy
60
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
92
BGL alert for Jul 3
Blue Gold [BGL] is down 20.3% over the past day.
Sell
18
CNC alert for Jul 3
Centene [CNC] is down 1.3% over the past day.
Sell
12
MOH alert for Jul 3
Molina Healthcare [MOH] is up 0.3% over the past day.
